Not long after lending its support to a documentary aimed at shining a light on the often-overlooked stories of women with ...

The status of the CDC’s vaccine advisory panel was thrown into further disarray this week after an outspoken member of the Advisory Committee on Immunization Practices (ACIP)—whose appointment was ...

With patents expiring today in India for Novo Nordisk’s popular diabetes and obesity drugs Ozempic and Wegovy, more than 40 generic drug makers are expected to begin launching their cheaper versions ...

Everyone’s favorite bracket challenge has returned. That’s right—it’s time once again for Fierce Pharma Marketing’s annual ...

The last available hemophilia gene therapy is temporarily unavailable, according to CSL Behring.  | The company is working ...

A new bill introduced in the Maryland House of Delegates requests that pharmas be more specific about the brands related to ...

Rhythm Pharmaceuticals is switching up the tempo for its melanocortin-4 receptor (MC4R) agonist Imcivree. | The new FDA nod makes Rhythm Pharma's Imcivree the first approved drug for acquired ...

In a bid to expand its reach in the attention-deficit/hyperactivity disorder (ADHD) market, Collegium Pharmaceutical has struck a deal to ...

Still basking in the afterglow of its Wegovy pill launch earlier this year, Novo has achieved another victory as it strives to make the most out of its blockbuster GLP-1 drug in an increasingly ...

With a fresh phase 3 win for Kerendia, Bayer is one step closer to pushing the ascendant drug into a much broader population ...

Some three weeks into the U.S. and Israel’s war with Iran, the expanding conflict’s impact on energy prices and shipping in ...

China has approved the world's first commercial brain-computer interface. AstraZeneca is building new cell therapy centers in Shanghai. | China approved the world's first commercial brain-computer ...